WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) — Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (“Tevogen”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Salesforce CEO Marc Benioff on receiving the Yale Legend in Leadership Award for highlighting that business success must coexist with social prosperity at the bi-annual CEO Summit. The Yale Legend in Leadership Award was created 35 years ago to honor current and former CEOs who serve as living legends to inspire chief executives across industries, sectors, and nations.
“I share Marc’s belief that business success must coexist with social prosperity,” said Dr. Ryan Saadi. “As a Yale graduate and a member of the Yale School of Public Health Leadership Council, it was a distinct pleasure to join Yale School of Management Senior Associate Dean, Jeffrey Sonnenfeld and business pioneers including Nikesh Arora, CEO, Palo Alto Networks; Steven Bandrowczak, CEO, Xerox; Ivan Seidenberg, Former Chair & CEO, Verizon; Brian Moynihan, Chair & CEO, Bank of America; Ken Moelis, Founder, Chair & CEO, Moelis & Company; Bob Iger, CEO, The Walt Disney Company; Jeffrey Bewkes, Former Chair & CEO, Time Warner; Mary Barra, Chair & CEO, General Motors; James Quincey, Chair & CEO, The Coca-Cola Company; Glenn Fogel, President & CEO, Booking Holdings; Michel Doukeris, CEO, Anheuser-Busch InBev; Jacek Olczak, CEO, Philip Morris International; Reuben Mark, Former CEO, Colgate-Palmolive Company; Michael Dell, Chair & CEO, Dell Technologies; Brian Tyler, CEO, McKesson Corporation; Christian Ulbrich, Global CEO, JLL; John W. Jackson, Former CEO, Celgene; James Taiclet, Chair, President & CEO, Lockheed Martin; Kathy Warden, Chair, President & CEO, Northrop Grumman; Lynn Good, Chair, President & CEO, Duke Energy; David Cote, Former Chair & CEO, Honeywell International; Arvind Krishna, Chair & CEO, IBM”.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
- Rock N Block Turf N Hardscapes Transforms Las Vegas Outdoor Spaces With Expert Landscaping Services - June 30, 2025
- Oliveda International, Inc. (OLVI) Subsidiary Olive Tree People Canada Inc. Brings Its Waterless Beauty to Canada in July 2025 - June 30, 2025
- Western Uranium & Vanadium Announces Results of AGM and Appoints New Transfer Agent - June 30, 2025
